Study Evaluating Biomarkers in Patients With Colorectal Cancer and Native KRAS Treated With Chemotherapy + Cetuximab
Status:
Completed
Trial end date:
2017-12-21
Target enrollment:
Participant gender:
Summary
Advanced colorectal cancer (ACRC) is a heterogeneous disease and classification of patients
is nowadays inefficient. Roughly twenty per cent of patients present with favorable figures
(less than 4 liver nodules and less than 5 cm) and are suitable for local treatments (surgery
or local-ablative therapies). Additionally, 10-15% of patients have poor performance status
(PS >2) or are severe disabled due to geriatric syndromes or/and co-morbid diseases that
preclude any treatment strategies than best supportive care alone. The rest of patients (fit
patients not suitable for radical treatments) constitute the population of patients treated
with palliative therapies. Despite of it not all these patients have the same prognosis.
Patients with PS 0,1 and levels of LDH Phase:
Phase 2
Details
Lead Sponsor:
Grupo Espanol Multidisciplinario del Cancer Digestivo